Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Active not recruiting 4Unknown 2Recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 99INDUSTRY 32NIH 6OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Ovarian Neoplasms 23Breast Neoplasms 22Lung Neoplasms 19Lymphoma 18Carcinoma, Ovarian Epithelial 18Neoplasm Metastasis 14Colorectal Neoplasms 14Squamous Cell Carcinoma of Head and Neck 12Sarcoma 12Head and Neck Neoplasms 12Urinary Bladder Neoplasms 10Prostatic Neoplasms 10Colonic Neoplasms 10Central Nervous System Neoplasms 10Astrocytoma 10Rectal Neoplasms 9Multiple Myeloma 9Uterine Cervical Neoplasms 8Oligodendroglioma 8Mycosis Fungoides 8Fallopian Tube Neoplasms 8Adenocarcinoma of Lung 8Stomach Neoplasms 7Recurrence 7Melanoma 7Medulloblastoma 7Brain Neoplasms 7Sezary Syndrome 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6

Interventions

Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NETWORK × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT00895297 2011-12-07

Dasatinib

European Society for Blood and Marrow Transplantation

Phase 2 Terminated
50 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡